Our Team is Dedicated to Revolutionizing the Management of Diabetes
Our executive team are renowned professionals with more than 50 years experience in the medical device field. They lead an accomplished and dedicated team of R & D, operational, quality, and regulatory leaders and staff. Our medical and business advisory group is comprised of highly experienced clinicians, corporate, financial, legal and IP resource experts.
President and CEO
William (Bill) Markle is President and CEO of GlySens. Mr. Markle has a 30-year track record of successful product and global market development, clinical evaluation, and visionary leadership in the medical device field. He was formerly founder, President, and CEO of GluMetrics, Inc. At GluMetrics, he directed the successful development of continuous real-time sensing technology for intravascular glucose monitoring in the intensive care and operating room environment. Previously, he held senior executive positions in marketing and business development at Tensys Medical and Masimo Corporation, and related positions at Baxter Edwards Critical Care and American Hospital Supply. Mr. Markle is an MBA graduate of Pepperdine University and an engineering graduate of Duke University. He is a named inventor on numerous issued U.S. patents and published applications.
Chief Technology Officer, Founder
Joseph Lucisano, PhD founded GlySens along with David Gough of the University of California San Diego and currently serves as Chief Technology Officer. Dr. Lucisano received his BS and PhD in Bioengineering at UCSD and his MS in Aeronautics and Astronautics at Stanford University. He has more than 25 years of professional experience in the development and market introduction of novel glucose monitors as well as other implantable devices for healthcare applications. He previously directed glucose sensor development at VIA Medical Corporation, resulting in the product launch of the world’s first practical, patient-attached blood glucose sensor system, the VIA 1-01G. Earlier, Dr. Lucisano led a successful development effort focused on intravascular glucose sensor technology, which produced landmark human clinical trial results. He holds 18 U.S. patents on glucose sensors, monitors, and related technology.
“No other team is currently developing a similar device in the United States.”